Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2 phases), addition of amlodipine.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daiichi Sankyo Inc.; Daiichi Sankyo, Inc.
• Treatments: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Hydrochlorothiazide; Olmesartan; Olmesartan Medoxomil

Criteria

Inclusion Criteria:

• Stage 1 and 2 hypertension without treatment for at least 2 weeks

• Women with no risk of becoming pregnant

Exclusion Criteria:

• Study participation could result in risk to health of subject

• Cardiovascular disease

• Secondary hypertension or stage 3 hypertension

• Myocardial infarction within the last 6 months

• Congestive heart failure

• Pulmonary edema

• Valvular alterations or rheumatic cardiopathy

• Clinically relevant conduction disorders significant arrhythmias

• Alcohol or illicit drug use

• Medication abuse

• Pregnant or nursing women